Globeflex Capital’s Array Biopharma Inc ARRY Stock Holding History

Globeflex Capital’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-267	Closed	-$1K	–	700
2013 Q2	$1K	Buy	+267	New	+$1.44K	﹤0.01%	560

Other funds holding ARRY

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Globeflex Capital's ARRY Position: Q3 2013 in Review

Globeflex Capital sold out of Array Biopharma Inc (ARRY) in Q3 2013, closing a stake of 267 shares — an estimated $1K sold.

Globeflex Capital first reported a position in ARRY in Q2 2013 and held it in 1 quarter. The position peaked at $1K in Q2 2013. 134 funds tracked by Wall St. Rank hold ARRY as of Q3 2013.

Globeflex Capital reported no remaining Array Biopharma Inc position as of Q3 2013 after selling out during the quarter.
Globeflex Capital sold 267 Array Biopharma Inc shares in Q3 2013, an estimated $1K.
Globeflex Capital first reported a position in Array Biopharma Inc in Q2 2013 and held it in 1 quarter.
Globeflex Capital's Array Biopharma Inc position peaked at $1K in Q2 2013.
134 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2013.

Based on Globeflex Capital's 13F filing for Q3 2013, filed 14 Nov 2013.